Trial Profile
Phase I/II Trial of IMC-A12 in Combination With Temsirolimus in Patients With Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Temsirolimus (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 15 May 2018 Status changed from active, no longer recruiting to completed.
- 28 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 01 Jul 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.